GSK Proposal For Novel Delivery NRT Leaves FDA Doubting 'Real World' Efficacy

In briefing materials NDAC to consider NDA for first mouth spray delivery NRT, agency also questions whether GSK study data show product is safe for OTC access for consumers. DNDP notes the GSK's clinical trial "consistent with a prescription use setting" showed higher success second trial "designed to be consistent with typical OTC use."

FDASignBldg21Entrance_1200x675

Results from studies included in GlaxoSmithKline PLC's proposal for a mouth spray nicotine replacement therapy prompt the US Food and Drug Administration to question the product's "real world" efficacy.

In its briefing materials published 16 September for its Nonprescription Drugs Advisory Committee to consider GSK's new drug application...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from United States

More from North America